These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 35744805)

  • 1. Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data.
    Fishman P
    Molecules; 2022 Jun; 27(12):. PubMed ID: 35744805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice.
    Fishman P; Cohen S; Itzhak I; Amer J; Salhab A; Barer F; Safadi R
    Int J Mol Med; 2019 Dec; 44(6):2256-2264. PubMed ID: 31638172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A
    Cohen S; Barer F; Itzhak I; Silverman MH; Fishman P
    J Immunol Res; 2018; 2018():2310970. PubMed ID: 29862305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects.
    Fishman P; Stemmer SM; Bareket-Samish A; Silverman MH; Kerns WD
    Purinergic Signal; 2023 Sep; 19(3):513-522. PubMed ID: 36781824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma.
    Etzion O; Bareket-Samish A; Yardeni D; Fishman P
    Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
    Safadi R; Braun M; Francis A; Milgrom Y; Massarwa M; Hakimian D; Hazou W; Issachar A; Harpaz Z; Farbstein M; Itzhak I; Lev-Cohain N; Bareket-Samish A; Silverman MH; Fishman P
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1405-1415. PubMed ID: 34671996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenosine A
    Duangrat R; Parichatikanond W; Chanmahasathien W; Mangmool S
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways.
    Itzhak I; Bareket-Samish A; Fishman P
    Biomolecules; 2023 Oct; 13(11):. PubMed ID: 38002266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adenosine A3 receptor agonist inhibits DSS-induced colitis in mice through modulation of the NF-κB signaling pathway.
    Ren T; Tian T; Feng X; Ye S; Wang H; Wu W; Qiu Y; Yu C; He Y; Zeng J; Cen J; Zhou Y
    Sci Rep; 2015 Mar; 5():9047. PubMed ID: 25762375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A₃ adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action.
    Cohen S; Barer F; Bar-Yehuda S; IJzerman AP; Jacobson KA; Fishman P
    Mediators Inflamm; 2014; 2014():708746. PubMed ID: 25374446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the A
    Cohen S; Fishman P
    Drug Des Devel Ther; 2019; 13():491-497. PubMed ID: 30787591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.
    Fishman P; Cohen S
    Clin Rheumatol; 2016 Sep; 35(9):2359-62. PubMed ID: 26886128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis.
    Fishman P; Bar-Yehuda S; Madi L; Rath-Wolfson L; Ochaion A; Cohen S; Baharav E
    Arthritis Res Ther; 2006; 8(1):R33. PubMed ID: 16507132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CF102 an A3 adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver.
    Cohen S; Stemmer SM; Zozulya G; Ochaion A; Patoka R; Barer F; Bar-Yehuda S; Rath-Wolfson L; Jacobson KA; Fishman P
    J Cell Physiol; 2011 Sep; 226(9):2438-47. PubMed ID: 21660967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncovering the Mechanisms of Adenosine Receptor-Mediated Pain Control: Focus on the A
    Coppi E; Cherchi F; Lucarini E; Ghelardini C; Pedata F; Jacobson KA; Di Cesare Mannelli L; Pugliese AM; Salvemini D
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A3 Adenosine Receptor Agonist Inhibited Survival of Breast Cancer Stem Cells via GLI-1 and ERK1/2 Pathway.
    Jafari SM; Panjehpour M; Aghaei M; Joshaghani HR; Enderami SE
    J Cell Biochem; 2017 Sep; 118(9):2909-2920. PubMed ID: 28230290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the A
    Singh AK; Mahalingam R; Squillace S; Jacobson KA; Tosh DK; Dharmaraj S; Farr SA; Kavelaars A; Salvemini D; Heijnen CJ
    Acta Neuropathol Commun; 2022 Jan; 10(1):11. PubMed ID: 35093182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the A3 adenosine receptor for glaucoma treatment (review).
    Fishman P; Cohen S; Bar-Yehuda S
    Mol Med Rep; 2013 Jun; 7(6):1723-5. PubMed ID: 23563604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of adenosine A3 receptor inhibits inflammatory cytokine production in colonic mucosa of patients with ulcerative colitis by down-regulating the nuclear factor-kappa B signaling.
    Ren TH; Lv MM; An XM; Leung WK; Seto WK
    J Dig Dis; 2020 Jan; 21(1):38-45. PubMed ID: 31714673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Status in the Design and Development of Agonists and Antagonists of Adenosine A3 Receptor as Potential Therapeutic Agents.
    Mailavaram RP; Al-Attraqchi OHA; Kar S; Ghosh S
    Curr Pharm Des; 2019; 25(25):2772-2787. PubMed ID: 31333098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.